Osteoporosis
is increasingly prevalent worldwide, representing
a major health burden. However, there is a lack of nutritional strategies
for osteoporotic therapy. Phytosterols, as natural bioactive compounds,
have the potential to alleviate osteoporosis. In this study, a glucocorticoid-induced
osteoporosis mouse model and treatment with low and high concentrations
of phytosterols for 4 weeks were established. The results demonstrated
that compared to the control group, low-concentration phytosterols
(LP) (0.3 mg/mL) increased bone mass, improved trabecular microstructure,
reduced serum levels of cross-linked C-telopeptide of type I collagen
(CTX-1), and elevated serum levels of 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3). Conversely, high-concentration
phytosterols (0.5 mg/mL) showed no effect. Additionally, we validated
the effect of LP in ameliorating osteoporosis using an ovariectomized
(OVX)-induced osteoporosis mouse model. Mechanistically, phytosterols
altered the microbial composition to counteract glucocorticoid-induced
gut microbiota disorder and improve the length and morphology of the
small intestine. Particularly, based on selection strategy and correlation
analysis, phytosterols increased the relative abundance of Ruminococcus and decreased the relative abundance of Bilophila, which were significantly associated with glucocorticoid-induced
osteoporosis indications. Overall, these findings suggest that phytosterols
regulate gut microbiota to increase bone mass, thereby exerting an
antiosteoporotic effect.